At a glance
ClinicalIndex Comparison RecordN/ACompleted· 300 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Mutation Profile Detection, Therapeutic Resistance and Clonal Evolution Assessed With Liquid Biopsy of Advanced NSCLC Patients in China
In Brief
An observational study for Lung Neoplasms and 3 related conditions. Completed, enrolled 300 participants across 14 sites.
Detailed Summary
To evaluate the concordance of sensitizing mutations detected between paired plasma and tissue samples; the correlation between the clonal status of sensitizing mutations and targeted therapy response; and the prognostic impact of the relative abundance of sensitizing / resistance mutations.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLung Neoplasms, Lung Cancer, Nonsmall Cell, Adenocarcinoma of Lung, Squamous Cell Lung Cancer
CountriesChina
CollaboratorsShanghai Chest Hospital
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartFeb 2017
First PostedFeb 2017
Primary CompletionDec 2019
Study CompletionJan 2020
TodayJul 2026
First PostedFeb 23, 2017
Enrollment StartFeb 22, 2017
Primary CompletionDec 31, 2019
Study CompletionJan 30, 2020
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 9.4 years ago